This article is more than 5 years old. Information may no longer be current.
Phakic IOL can play role in treatment of anisometropic myopia
Click Here to Manage Email Alerts
Phakic IOL implantation may be considered to reduce or eliminate highly significant anisometropic myopia in children, according to a recent study.
Amir Pirouzian, MD, and colleagues at San Diego Children’s Hospital assessed the efficacy of implantation of a phakic IOL in four pediatric patients with anisometropic myopia. None of the patients were adherent to contact lens therapy, and all four had dense amblyopia. The patients were between the ages of 2 and 7 years old at the time of IOL insertion. The patients underwent the implantation of the Advanced Medical Optics Verisyse IOL in the more myopic eye. Mean follow-up was 3 to 6 months from the time of IOL implantation.
Visual acuity improved by more than four lines in two patients. All patients had enhanced physical activity, coordination and improved social interaction by 2 months postop.
“Anterior chamber phakic IOLs provide another alternative in treatment for noncompliant or difficult anisometropic myopic patients who do not adhere to contact lens therapy,” the researchers said.
The study is published in the February issue of the Journal of American Association for Pediatric Ophthalmology and Strabismus.